Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm

American Journal of Kidney Diseases

Volumn 61, Issue 2, 2013, Pages 238-246

  Skali, Hicham ^a   Lin, Julie ^a   Pfeffer, Marc A ^a   Chen, Chao Yin ^b   Cooper, Mark E ^c   McMurray, John J V ^d   Nissenson, Allen R ^e,f   Remuzzi, Giuseppe ^g   Rossert, Jerome ^b   Parfrey, Patrick S ^h   Scott Douglas, Nairne W ⁱ   Singh, Ajay K ^a   Toto, Robert ^j   Uno, Hajime ^k   Ivanovich, Peter ^l  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DAVITA INC   (United States)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h Health Sciences Centre   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j UNIVERSITY OF TEXAS AT DALLAS   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Anemia; erythropoiesis stimulating agents; placebo

Indexed keywords

CREATININE; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROTEIN; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DOUBLE BLIND PROCEDURE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; STATISTICAL SIGNIFICANCE; TRANSFERRIN BLOOD LEVEL;

AGED; ANEMIA; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84872308317     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.08.043     Document Type: Article

References (20)

1. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
2. A.J. Collins, S. Li, W. St Peter Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39% J Am Soc Nephrol 12 2001 2465 2473
3. J.W. Eschbach, M.H. Abdulhadi, J.K. Browne Recombinant human erythropoietin in anemic patients with end-stage renal disease Results of a phase III multicenter clinical trial Ann Intern Med 111 1989 992 1000
4. Canadian Erythropoietin Study Group Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis BMJ 300 1990 573 578
5. A.K. Singh, L. Szczech, K.L. Tang CHOIR Investigators Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
6. T.B. Drüeke, F. Locatelli, N. Clyne CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084
7. P.S. Parfrey, R.N. Foley, B.H. Wittreich, D.J. Sullivan, M.J. Zagari, D. Frei Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease J Am Soc Nephrol 16 2005 2180 2189
8. M.A. Pfeffer, E.A. Burdmann, C.-Y. Chen TREAT Investigators A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
9. M.A. Pfeffer Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo Am J Kidney Dis 51 2008 366 369
10. Food and Drug Administrattion (FDA) FDA Drug Safety Communication: modified dosing recommendations to improve the safe use of erythropoiesis- stimulating agents (ESAs) in chronic kidney disease Published June 24, 2011 http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm Accessed July 23, 2012
11. H. Skali, H.-H. Parving, P.S. Parfrey TREAT Investigators Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience Circulation 124 2011 2903 2908
12. M.A. Pfeffer, E.A. Burdmann, C.-Y. Chen TREAT Investigators Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Am J Kidney Dis 54 2009 59 69
13. T.-C.H. Mix, R.M. Brenner, M.E. Cooper Rationale - Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease Am Heart J 149 2005 408 413
14. S.D. Solomon, H. Uno, E.F. Lewis Trial to Reduce Cardiovascular Events With Aranesp Therapy TREAT Investigators Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
15. HemoCue B-Hemoglobin Package Insert HemoCue, Inc A Quest Diagnostics Company 2010
16. K. Kalantar-Zadeh, G.R. Aronoff Hemoglobin variability in anemia of chronic kidney disease J Am Soc Nephrol 20 2009 479 487
17. A. Ishani, E. Weinhandl, Z. Zhao Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction J Am Coll Cardiol 45 2005 391 399
18. W.C. Winkelmayer, R. Kewalramani, M. Rutstein, S. Gabardi, T. Vonvisger, A. Chandraker Pharmacoepidemiology of anemia in kidney transplant recipients J Am Soc Nephrol 15 2004 1347 1352
19. D. Nordenberg, R. Yip, N.J. Binkin The effect of cigarette smoking on hemoglobin levels and anemia screening JAMA 264 1990 1556 1559
20. N. Milman, A.N. Pedersen Blood haemoglobin concentrations are higher in smokers and heavy alcohol consumers than in non-smokers and abstainers: should we adjust the reference range? Ann Hematol 88 2009 687 694